% | $
Quotes you view appear here for quick access.

pSivida Corp. Message Board

  • mickmack50 mickmack50 May 2, 2013 9:33 AM Flag

    Eylea Gaining Market Share

    Allergan just announced lackluster trial results for a competitor drug in the eye space. Regeneron's Eylea is the drug to beat, due to it's efficacy and the fact that you can receive injections "every 6 weeks". Now we know that 2 undisclosed "global"pharmas are tech evaluating Tethadur for sustained release proteins. Do the math.

    Regeneron in the past two years has vaulted seemingly out of nowhere to become one of the world's biggest biotechnology companies, thanks largely to Eylea.

    The company has repeatedly raised its sales forecasts for the drug, which is injected into the eye, as it steadily steals market share from Lucentis.

    Some specialty pharmacies also use Roche's Avastin cancer drug, which works the same way as Lucentis, but is far less expensive, when divided into smaller portions for treating macular degeneration.

    Roche has said that dividing Avastin through a procedure not closely monitored by health regulators, called compounding, could compromise its sterility.

    Regeneron Chief Executive Leonard Schleifer said in a recent interview that sales of Eylea could jump sharply if potential rivals stumble, or if U.S. regulators clamp down on the compounding of Avastin for eye use.

    Moreover, he said some analysts believe Eylea sales could swell if it is approved for a new indication called diabetic macular edema now in late-stage trials. Lucentis is already approved for the condition.

    "So Eylea is a growth story unto itself, with lots of room to still grow," Schleifer said.

3.38-0.06(-1.74%)Feb 5 4:00 PMEST